Hil-Invent

Hil-Invent GmbH is an investment firm headquartered in Salzburg, Austria, with a core mission to fund innovative companies and groundbreaking technologies. The firm strategically supports ventures, particularly within the dynamic biotechnology sector, that are actively advancing proprietary technologies to foster significant growth and innovation. A prominent example in its diverse portfolio is Captain T Cell, a cutting-edge biotech spin-off originating from the Max Delbrück Center, which specializes in developing advanced cellular therapies. In addition to its focus on life sciences, Hil-Invent's investment strategy thoughtfully extends to encompass promising opportunities within the consumer services industry. While specific financial metrics, such as total funding raised or assets under management, remain undisclosed, the firm consistently seeks to back high-potential startups. Hil-Invent GmbH was established in 2017, though the identities of its founders are not publicly known.